Fig. 3: Prophylactic treatment with uPAR targeting CAR T cells rescue age-related defects in intestinal epithelium integrity.
a, Experimental scheme for b–f: Young (3 months) mice were treated with 0.5 × 106 untransduced T cells (UT) or uPAR CAR T cells (m.uPAR-m.28z). Mice were harvested 15 months after infusion at the age of 18 months. b, Percentage of CD45.1 and CD3 double positive cells in the intestinal crypts (n = 3 for UT, n = 4 for m.uPAR-m.28z). c, Representative staining of uPAR, SA-β-gal and Olfm4 in proximal jejunum. d, Percentage of histological area with uPAR+ cells per field as determined by immunohistochemistry in the proximal jejunum (n = 3 for UT, n = 4 for m.uPAR-m.28z). e, Percentage of histological area with SA- β-gal+ cells in the proximal jejunum (n = 3 for UT, n = 4 for m.uPAR-m.28z). f, Normalized plasma levels of FITC-Dextran 4 h after oral gavage (n = 7 for UT, n = 10 for m.uPAR-m.28z). Shown are results of two independent experiments (f) or one independent experiment (b–e). Data are mean ± s.e.m. (b,d–f). Significance was determined by two-tailed unpaired Student’s t-test (b,d–f). Illustration was created with Biorender.com (a).
